 | Up a level |
Journal Article
Balavarca, Y., Pearce, K., Norden, J., Collin, M., Jackson, G., Holler, E., Dressel, R., Kolb, H-J, Greinix, H., Socie, G., Toubert, A., Rocha, V., Gluckman, E., Hromadnikova, I., Sedlacek, P., Wolff, D., Holtick, U., Dickinson, A. and Bickeboeller, H. (2015). Predicting survival using clinical risk scores and non-HLA immunogenetics. Bone Marrow Transplant., 50 (11). S. 1445 - 1453. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Greinix, H., Beohou, E., van der Werf, S., Niederwieser, D., Blaise, D., Dreger, P., Arnold, R., Meijer, E., Sengeloev, H., Cornelissen, J., Hallek, M., Socie, G., Chevallier, P., Ganser, A., Milpied, N., Maertens, J., Petersen, E., Afanasyev, B., Ehninger, G., Fegueux, N., Jindra, P., Kroeger, N., Montoto, S., Nagler, A. and Duarte, R. (2017). Impact of ATG use on the outcome of patients with hematological malignancies undergoing reduced-intensity conditioning for allogeneic hematopoietic cell transplantation. Bone Marrow Transplant., 52. S. S61 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Scheid, C., de Wreede, L., van Biezen, A., Goehring, G., Koenecke, C., Volin, L., Maertens, J., Finke, J., Schaap, N., Socie, G., Passweg, J., Cornelissen, J., Beelen, D., de Witte, T. and Kroeger, N. (2014). THE REVISED IPSS (IPSS-R) AT TRANSPLANT PREDICTS OVERALL AND RELAPSE-FREE SURVIVAL AFTER ALLOGENEIC STEM CELL TRANSPLANTATION IN MDS/SAML: A RETROSPECTIVE ANALYSIS OF THE EBMT CHRONIC MALIGNANCIES WORKING PARTY. Bone Marrow Transplant., 49. S. S93 - 2. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, Sicre F., Na, I. -K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Grigoleit, G. U., Kuball, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N. (2015). Ruxolitinib for corticosteroid-refractory graft-versus-host disease: analysis of 95 patients treated at multiple medical centers. Oncol. Res. Treat., 38. S. 43 - 45. BASEL: KARGER. ISSN 2296-5262
Zeiser, R., Burchert, A., Lengerke, C., Verbeek, M., Maas-Bauer, K., Metzelder, S. K., Spoerl, S., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Ajib, S., de Fontbrune, F. S., Na, I-K, Penter, L., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Bertz, H., Marks, R., Luebbert, M., Waesch, R., Scheid, C., Stoelzel, F., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Brune, M., Spyridonidis, A., Schmitt-Graeff, A., van der Velden, W., Huls, G., Mielke, S., Grigoleit, G. U., Kuball, J., Flynn, R., Ihorst, G., Du, J., Blazar, B. R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Peschel, C., Neubauer, A., Finke, J., Duyster, J. and von Bubnoff, N. (2015). Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey. Leukemia, 29 (10). S. 2062 - 2069. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Zeiser, R., Lengerke, C., Spoerl, S., Maas-Bauer, K., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Sicre-de-Fontbrune, F., Na, I-K, Ajib, S., Verbeek, M., Nogai, H., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Illert, L., Bertz, H., Marks, R., Waesch, R., Hackanson, B., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Finke, J., Peschel, C., Duyster, J. and von Bubnoff, N. (2015). High response rates in patients treated with ruxolitinib for corticosteroid-refractory Graft-versus-host disease: analysis including 13 Transplant Centers. Bone Marrow Transplant., 50. S. S22 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Zeiser, R., Lengerke, C., Spoerl, S., Maas-Bauer, K., Ditschkowski, M., Ecsedi, M., Sockel, K., Ayuk, F., Sicre-de-Fontbrune, F., Na, I-K, Ajib, S., Verbeek, M., Nogai, H., Holtick, U., Wolf, D., Schuler, E., Meyer, E., Apostolova, P., Illert, L., Bertz, H., Marks, R., Waesch, R., Hackanson, B., Scheid, C., Ordemann, R., Bug, G., Kobbe, G., Negrin, R., Arnold, R., Kroeger, N., Passweg, J., Halter, J., Socie, G., Beelen, D., Finke, J., Peschel, C., Duyster, J. and von Bubnoff, N. (2015). High response rates in patients treated with ruxolitinib for corticosteroid-refractory Graft-versus-host disease: analysis including 13 Transplant Centers. Bone Marrow Transplant., 50. S. S22 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365